Cysteamine
Side effects
Options:
Show MedDRA Preferred Terms
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
Body temperature increased
|
very common, 22% - 28%
|
|
|
x
|
x
|
x
|
x
|
Vomiting
|
very common, 12% - 35%
|
|
|
x
|
x
|
x
|
x
|
Diarrhoea
|
postmarketing — 16% - 31%
|
|
|
x
|
x
|
x
|
x
|
Anorexia
|
very common, 2% - 33%
|
|
|
x
|
x
|
x
|
x
|
Lethargy
|
very common, 11% - 17%
|
|
|
x
|
x
|
x
|
x
|
Nausea
|
very common, 7% - 16%
|
|
|
x
|
x
|
x
|
x
|
Discomfort
|
0% - 14%
|
|
|
x
|
|
|
|
Rash
|
common, 7%
|
|
|
x
|
x
|
x
|
x
|
Asthenia
|
common
|
|
|
|
|
x
|
x
|
Dyspepsia
|
common
|
|
|
|
x
|
x
|
x
|
Gastroenteritis
|
common
|
|
|
|
x
|
x
|
x
|
Breath odour
|
common
|
|
|
x
|
x
|
x
|
x
|
Headache
|
common, 0% - 9%
|
|
x
|
x
|
x
|
x
|
x
|
Encephalopathy
|
common
|
|
|
x
|
x
|
x
|
x
|
Liver function test abnormal
|
common
|
|
|
|
|
x
|
x
|
Skin odour abnormal
|
common
|
|
|
|
|
x
|
x
|
Appetite absent
|
2% - 5%
|
|
|
x
|
|
|
|
Abdominal pain
|
postmarketing — 0% - 14%
|
|
|
x
|
x
|
x
|
x
|
Dizziness
|
0% - 5%
|
|
|
x
|
x
|
|
|
Anaphylactic shock
|
uncommon
|
|
|
x
|
|
x
|
x
|
Hallucination
|
uncommon
|
|
|
|
x
|
x
|
x
|
Leukopenia
|
uncommon
|
|
|
x
|
x
|
x
|
x
|
Nephrotic syndrome
|
uncommon
|
|
|
|
|
x
|
x
|
Nervousness
|
uncommon
|
|
|
|
x
|
x
|
x
|
Convulsion
|
uncommon
|
|
|
x
|
x
|
x
|
x
|
Gastrointestinal ulcer
|
uncommon
|
|
|
|
|
x
|
x
|
Hair colour changes
|
uncommon
|
|
|
|
|
x
|
x
|
Somnolence
|
uncommon
|
|
|
x
|
x
|
x
|
x
|
Gastrointestinal disorder
|
postmarketing
|
|
|
x
|
|
x
|
x
|
Leg pain
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Osteopenia
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Papilloedema
|
postmarketing
|
|
|
x
|
x
|
|
x
|
Pseudotumor
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Benign intracranial hypertension
|
postmarketing
|
|
|
x
|
x
|
|
x
|
Scoliosis
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Skin striae
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Joint hyperextension
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Compression fracture
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Skin fragility
|
postmarketing, uncommon
|
|
|
x
|
x
|
|
x
|
Genu valgum
|
postmarketing, uncommon
|
|
|
x
|
x
|
x
|
x
|
Anaemia
|
|
|
|
|
x
|
|
|
Ataxia
|
|
|
|
|
x
|
|
|
Mental disorder
|
|
|
|
|
|
x
|
x
|
Bone disorder
|
|
|
|
|
|
x
|
x
|
Confusional state
|
|
|
|
|
x
|
|
|
Connective tissue disorder
|
|
|
|
|
|
|
x
|
Constipation
|
|
|
|
|
x
|
|
|
Dehydration
|
|
|
|
|
x
|
|
|
Duodenitis
|
|
|
|
|
x
|
|
|
Fatigue
|
|
|
|
x
|
|
|
|
Glomerulonephritis membranous
|
|
|
|
|
|
x
|
x
|
Hypersensitivity
|
|
|
|
x
|
|
x
|
x
|
Hypertension
|
|
|
|
|
x
|
|
|
Immune system disorder
|
|
|
|
|
|
x
|
x
|
Nephritis interstitial
|
|
|
|
x
|
x
|
x
|
x
|
Nervous system disorder
|
|
|
|
|
|
x
|
x
|
Nightmare
|
|
|
|
|
x
|
|
|
Renal failure
|
|
|
|
|
x
|
|
|
Scotoma
|
|
|
x
|
|
|
|
|
Tremor
|
|
|
|
|
x
|
|
|
Urinary tract disorder
|
|
|
|
|
|
x
|
x
|
Urticaria
|
|
|
|
x
|
x
|
|
|
Mood swings
|
|
|
|
|
x
|
|
|
Hepatic function abnormal
|
|
|
|
|
x
|
|
|
Eye pain
|
|
|
x
|
|
|
|
|
Phosphatase alkaline increased
|
|
|
|
x
|
|
|
|
Malnutrition
|
|
|
|
|
|
x
|
x
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
|
|
|
x
|
x
|
Decreased appetite
|
|
|
|
x
|
|
|
|
Thinking abnormal
|
|
|
|
|
x
|
|
|
Bone lesion
|
|
|
|
|
|
x
|
x
|
Urine odour abnormal
|
|
|
|
x
|
|
|
|
Redness
|
|
|
x
|
|
|
|
|
Intravascular large B-cell lymphoma
|
|
|
|
|
|
x
|
x
|
Hyperkinesia
|
|
|
|
|
x
|
|
|
Feeling jittery
|
|
|
|
|
x
|
|
|
Blood and lymphatic system disorders
|
|
|
|
|
|
x
|
x
|
Cerebral ischaemia
|
|
|
|
|
|
x
|
x
|
Gastrointestinal ulcer haemorrhage
|
|
|
|
x
|
x
|
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 4 |
Source: | FDA Structured Product Label |
---|
Side effects: | 38 |
Source: | FDA Structured Product Label |
---|
Side effects: | 48 |
Source: | FDA Structured Product Label |
---|
Side effects: | 48 |
Source: | EMA |
---|
Side effects: | 52 |
Source: | EMA |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|